The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025.
Pancreatic cancer therapy is recommended by clinicians for early detection of cancer. Pancreatic cancer generally diagnosed at a later stage, since the symptoms are not easily detected or diagnosed. Factors such as, chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. Biologics therapies attack the tumor cells directly or by stimulating the immune system to target the tumor cells indirectly. The increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies. The report would be of an interest to various stakeholders operating in the pancreatic cancer therapy market. These stakeholders include pancreatic cancer therapy associations, research & consulting firms, distributors of pancreatic cancer therapy research products, manufacturers of pancreatic cancer therapy products, and consumables, research institutes & clinical research organizations (CROs), and venture capitalists.
Get sample PDF Report @ https://www.theinsightpartners.com/sample/TIPMD00002009/
Pancreatic cancer therapy market is segmented into type, and therapy. On the basis of type, the market is segmented into exocrine pancreatic cancer and endocrine pancreatic cancer. The market based on the therapy is segmented into biologic, chemotherapy and others.
The major players operating in the market include Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc. among others.
For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences. AMRO BioSciences is engaged into number of drugs for cancer. The clinical trial explores a drug (pegilodecakin) which is ongoing for the pancreatic cancer. The drug is into phase III of the clinical trials. The acquisition will enhance the therapy products for the Eli Lilly and Company.
The report analyzes factors affecting market from both demand and supply side and further evaluates pancreatic cancer therapy market dynamics effecting the pancreatic cancer therapy market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the market in these regions. The report also includes the profiles of key manufacturing companies along with their SWOT analysis and market strategies.
The objective of the study is to describe, define, and forecast the pancreatic cancer therapy market by type, therapy, and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall pancreatic cancer therapy market.
The report segments the global pancreatic cancer therapy market as follows:
Global Pancreatic Cancer Therapy Market – By Type
Global Pancreatic Cancer Therapy Market – By Therapy
Global Pancreatic Cancer Therapy Market – By Geography
Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPMD00002009/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.